89 completed, 17 unknown, 11 recruiting, 6 active not recruiting. 35 Phase 3, 23 Phase 4, 22 Phase 2, 14 Not applicable, 8 Phase 1.
Follow edoxaban: new trials by email Literature Review of edoxaban trials Research Report on edoxaban
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial Edoxaban 15 mg, Aspirin or clopidogrel - Stroke, Ischemic | Phase 3 | Recruiting | Sunnybrook Health Sciences Centre | 1204 | 2026-11-01 | 2026-10-23 |
| Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism edoxaban, Apixaban - Venous Thromboembolism, Active Cancer | Phase 4 | Not yet recruiting | Samsung Medical Center | 2300 | 2026-11-01 | 2026-10-01 |
| Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy Rivaroxaban, or Edoxaban , or Apixaban , or Dabigatran, Aspirin - Stroke, Acute Ischemic Stroke | Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 680 | 2026-08-15 | 2026-08-05 |
| Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease Edoxaban, Apixaban - Atrial Fibrillation (AF), Coronary Arterial Disease (CAD) | Phase 4 | Recruiting | Samsung Medical Center | 3000 | 2026-07-20 | 2026-08-10 |
| STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism Anticoagulants, Thrombolytic Agents, Mechanical Thrombectomy Devices - Pulmonary Embolism, Venous Thromboembolism | Not yet recruiting | Nanjing First Hospital, Nanjing Medical University | 1300 | 2026-06-01 | 2026-05-22 | |
| Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia Dabigatran, Apixaban, edoxaban - Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia | Phase 4 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 300 | 2026-01-15 | 2026-09-24 |
| A Real World Evidence Retrospective Data Collection Study of Edoxaban and Rivaroxaban Edoxaban, Rivaroxaban - Atrial Fibrillation, Renal Dysfunction | Completed | Daiichi Sankyo | 8265 | 2025-12-25 | 2026-10-15 | |
| A Clinical Trial to Evaluate the Effect of Grapefruit Juice on the PK/PD of Edoxaban Edoxaban 60 MG [Lixiana], Edoxaban 60 MG [Lixiana] + Grapefruit Juice - Healthy | Phase 1 | Active not recruiting | Hyewon Chung | 14 | 2025-09-02 | 2025-09-16 |
| Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome Edoxaban 60 mg, Enoxaparin 40 mg - Nephrotic Syndrome, Hypoalbuminemia | Not applicable | Not yet recruiting | Peking University People's Hospital | 60 | 2025-09-01 | 2025-08-11 |
| Low Dose Edoxaban in Elderly Patients With AF and a History of Stroke edoxaban, Edoxaban 30 mg - Elderly, Atrial Fibrillation (AF) | Phase 2 / Phase 3 | Not yet recruiting | National Taiwan University Hospital | 300 | 2025-04-01 | 2025-04-02 |
| Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage Direct-Acting Oral Anticoagulants (used as per local standard practice) - Traumatic Intracranial Haemorrhage | Phase 3 | Recruiting | Walton Centre NHS Foundation Trust | 1084 | 2025-03-10 | 2026-06-18 |
| Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE) Anticoagulant Oral - Atrium; Fibrillation, Chronic Kidney Diseases | Phase 4 | Recruiting | Hospital Sirio-Libanes | 1500 | 2024-12-18 | 2025-02-21 |
| To Compare and Evaluate the Oral Bioavailability of Edoxaban 60 mg Film Coated Tablet With That of Lixiana® 60 mg Filmtabletten (Film Coated Tablet) (Edoxaban) in Healthy, Adult, Human Subjects Under Fasting Conditions Lixiana® Film Coated Tablet, Edoxaban Film Coated Tablet - Prevention of Stroke or Systemic Embolism, Deep Vein Thrombosis (DVT) | Not applicable | Completed | Humanis Saglık Anonim Sirketi | 42 | 2024-08-30 | 2025-04-20 |
| Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF LAmbre PlusTM Left Atrial Appendage Closure System, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa) - Atrial Fibrillation, Left Atrial Appendage Thrombosis | Not applicable | Withdrawn | Brian O'Neill MD | 2024-06-01 | 2025-11-04 | |
| Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulant VMX-C001, Placebo, Rivaroxaban 20 mg Oral Tablet - Coagulation Disorder | Phase 1 | Completed | VarmX B.V. | 40 | 2024-02-21 | 2026-09-09 |
| EdOxaban in fRagIle Patients With Percutaneous Endoscopic GAstrostoMy and atrIal fIbrIllation Edoxaban, No Edoxaban - Atrial Fibrillation, Fragility | Not applicable | Unknown | Azienda Ospedaliero Universitaria Maggiore della Carita | 168 | 2024-02-01 | 2024-02-29 |
| DOAC in Patients with Child a or B Liver Cirrhosis Apixaban 5 MG [Eliquis], Edoxaban 60 MG [Lixiana] - Liver Cirrhosis | Phase 2 | Recruiting | Centre Hospitalier Universitaire Vaudois | 40 | 2024-01-18 | 2025-02-13 |
| Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients Edoxaban - Thrombosis, Venous, Cancer | Phase 3 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 366 | 2023-11-30 | 2023-11-29 |
| The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet - Deep Vein Thrombosis, Pulmonary Embolism | Phase 4 | Active not recruiting | Herlev and Gentofte Hospital | 5000 | 2023-04-01 | 2025-05-15 |
| The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet - Atrial Fibrillation, Atrial Flutter | Phase 4 | Active not recruiting | Herlev and Gentofte Hospital | 11000 | 2023-04-01 | 2025-05-18 |
Showing 20 of 135. Sign in to see all of them.
Atrial Fibrillation (56) · Venous Thromboembolism (21) · Venous Thrombosis (18) · Stroke (15) · Thrombosis (14) · Ischemic Stroke (11) · Thromboembolism (9) · Pulmonary Embolism (8) · Hemorrhage (7) · Neoplasms (7) · Hemostatic Disorders (6) · Coronary Artery Disease (5) · Embolism (5) · Intracranial Hemorrhages (4) · Aortic Valve Stenosis (3)
Daiichi Sankyo (22) · Daiichi Sankyo Co., Ltd. (10) · Samsung Medical Center (4) · Bayer (3) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (3) · Population Health Research Institute (3) · Portola Pharmaceuticals (3) · Herlev and Gentofte Hospital (2) · Insel Gruppe AG, University Hospital Bern (2) · National Taiwan University Hospital (2) · Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. (2) · Pfizer (2) · University of Edinburgh (2) · VarmX B.V. (2) · Alliance Foundation Trials, LLC. (1)
United States (32) · South Korea (25) · Germany (24) · United Kingdom (24) · Italy (22) · Spain (21) · Canada (20) · Japan (16) · Belgium (15) · Netherlands (15) · France (14) · Switzerland (13) · Taiwan (13) · Austria (11) · Denmark (11)
Takeshi Fuji (4) · Gunnar H Gislason, MD, PhD (2) · Scott Rasmussen, MD (2) · Andreas Gotte, Prof., MD (1) · Andrew Chapman, MBChB PhD (1) · Armin Schultz, MD (1) · Ashkan Shoamanesh, MD, FRCPC (1) · Brian Buck, MD (1) · Brian O'Neill, MD (1) · Carlo Gaudio, MD (1)
PMID 36700520, PMID 40014354, PMID 34022170, PMID 27980462, PMID 31492505, PMID 38098072, PMID 38881370, PMID 40925065, PMID 20665856, PMID 20723861, PMID 20934556, PMID 21861537, PMID 22398655, PMID 23991658, PMID 24251359, PMID 24302269, PMID 24680549, PMID 24682348, PMID 24947287, PMID 25047458, PMID 25060026, PMID 25104527, PMID 25294589, PMID 25403645, PMID 25604089, PMID 25653574, PMID 25769357, PMID 25769361, PMID 25777666, PMID 25809373, PMID 25965706, PMID 26179767, PMID 26271200, PMID 26843482, PMID 26908401, PMID 26993976, PMID 27165711, PMID 27207971, PMID 27284271, PMID 27358434, PMID 27387994, PMID 27402235, PMID 27476789, PMID 27570090, PMID 27590218, PMID 27609678, PMID 27706467, PMID 27765196, PMID 27931603, PMID 28065447
2016 (6), 2015 (3), 2017 (2), 2023 (2), 2014 (1), 2018 (1), 2019 (1), 2025 (1)